<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095510</url>
  </required_header>
  <id_info>
    <org_study_id>0624-203</org_study_id>
    <secondary_id>2011-000369-11</secondary_id>
    <nct_id>NCT01095510</nct_id>
  </id_info>
  <brief_title>CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12</brief_title>
  <official_title>Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to evaluate: (1) the dose response and (2) the
      pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) administration of CINRYZE
      for the treatment of acute angioedema attacks in children above and below 25 kg and less than
      12 years of age with hereditary angioedema (HAE); and (3) to determine the safety and
      tolerability following IV administration of CINRYZE in this study population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject received CINRYZE for treatment of a single acute angioedema attack.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom</measure>
    <time_frame>Within 4 hours following treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Unequivocal Beginning of Relief of the Defining Attack Symptom</measure>
    <time_frame>Within 4 hours following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Resolution of the Attack</measure>
    <time_frame>Within 1 week following treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C1 Inhibitor (C1 INH) Antigen and Functional C1 INH Concentrations</measure>
    <time_frame>Pre-dose, 2, 4, 8 hours post dose on Day 1; Day 2, 3, 5, 8</time_frame>
    <description>Data was not reported due to change in planned analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>500 U CINRYZE (10-25 kg body weight)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of 500 U CINRYZE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 U CINRYZE (10-25 kg body weight)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of 1000 U CINRYZE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 U CINRYZE (&gt;25 kg body weight)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of 1000 U CINRYZE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 U CINRYZE (&gt;25 kg body weight)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV dose of 1500 U CINRYZE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CINRYZE</intervention_name>
    <arm_group_label>500 U CINRYZE (10-25 kg body weight)</arm_group_label>
    <arm_group_label>1000 U CINRYZE (10-25 kg body weight)</arm_group_label>
    <arm_group_label>1000 U CINRYZE (&gt;25 kg body weight)</arm_group_label>
    <arm_group_label>1500 U CINRYZE (&gt;25 kg body weight)</arm_group_label>
    <other_name>C1 inhibitor [human]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for this protocol, subjects must:

          1. Be at least 10 kg of body weight.

          2. Have a confirmed diagnosis of HAE.

          3. Have an acute HAE attack and be able to initiate treatment within 8 hours after onset
             of symptoms.

        Exclusion Criteria:

        To be eligible for this protocol, subjects must not:

          1. Have any active infectious illness.

          2. Have had a prior HAE attack and/or received any C1 INH product within 7 days prior to
             dosing with study drug.

          3. Have received therapy with antifibrinolytics (e.g., tranexamic acid), androgens (e.g.,
             danazol, oxandrolone, stanozolol, or testosterone), ecallantide (Kalbitor®), or
             icatibant (Firazyr®) within 7 days prior to dosing with study drug.

          4. Have a history of allergic reaction to C1 INH products, including CINRYZE (or any of
             the components of CINRYZE), or other blood products.

          5. Have participated in any other investigational drug evaluation within 30 days prior to
             dosing with study drug, or have previously received treatment with CINRYZE in this
             study at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Schranz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma &amp; Allergy Associates, P.C.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Asthma, Allergy and Immunology Clinical Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma and Allergy, PC</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Research Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma and Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Research Center, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marycliff Allergy Specialists</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Dept. of Dermatology and Allergy</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technical University Munich, ENT Clinic</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Allergy and Angioedema Outpatients Clinic, Kútvölgyi Clinical Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2014</results_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>CINRYZE</keyword>
  <keyword>C1 INH</keyword>
  <keyword>C1 inhibitor</keyword>
  <keyword>Pediatric</keyword>
  <keyword>PK/PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were not enrolled in the lower body weight category (10-25 kilograms [kg]) 1000 Units (U) dose group despite substantial recruitment efforts.</recruitment_details>
      <pre_assignment_details>Of 12 participants screened, 9 participants were enrolled and treated. The reason for 3 participants were screen failures as they did not meet the inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>500 U CINRYZE (10-25 kg Body Weight)</title>
          <description>Single intravenous (IV) dose of 500 U CINRYZE</description>
        </group>
        <group group_id="P2">
          <title>1000 U CINRYZE (10-25 kg Body Weight)</title>
          <description>Single IV dose of 1000 U CINRYZE</description>
        </group>
        <group group_id="P3">
          <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1000 U CINRYZE</description>
        </group>
        <group group_id="P4">
          <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1500 U CINRYZE</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>500 U CINRYZE (10-25 kg Body Weight)</title>
          <description>Single IV dose of 500 U CINRYZE</description>
        </group>
        <group group_id="B2">
          <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1000 U CINRYZE</description>
        </group>
        <group group_id="B3">
          <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1500 U CINRYZE</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B2" value="9" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="B3" value="10" lower_limit="8" upper_limit="11"/>
                    <measurement group_id="B4" value="9" lower_limit="6" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom</title>
        <time_frame>Within 4 hours following treatment</time_frame>
        <population>Intent-to-treat efficacy (ITT-E) population included all participants with baseline and at least one post-infusion investigator assessment of the hereditary angioedema (HAE) attack.</population>
        <group_list>
          <group group_id="O1">
            <title>500 U CINRYZE (10-25 kg Body Weight)</title>
            <description>Single IV dose of 500 U CINRYZE</description>
          </group>
          <group group_id="O2">
            <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1000 U CINRYZE</description>
          </group>
          <group group_id="O3">
            <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1500 U CINRYZE</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom</title>
          <population>Intent-to-treat efficacy (ITT-E) population included all participants with baseline and at least one post-infusion investigator assessment of the hereditary angioedema (HAE) attack.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Unequivocal Beginning of Relief of the Defining Attack Symptom</title>
        <time_frame>Within 4 hours following treatment</time_frame>
        <population>ITT-E population</population>
        <group_list>
          <group group_id="O1">
            <title>500 U CINRYZE (10-25 kg Body Weight)</title>
            <description>Single IV dose of 500 U CINRYZE</description>
          </group>
          <group group_id="O2">
            <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1000 U CINRYZE</description>
          </group>
          <group group_id="O3">
            <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1500 U CINRYZE</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Unequivocal Beginning of Relief of the Defining Attack Symptom</title>
          <population>ITT-E population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.25" upper_limit="1.75"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.25" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.25" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Resolution of the Attack</title>
        <time_frame>Within 1 week following treatment</time_frame>
        <population>ITT-E population.</population>
        <group_list>
          <group group_id="O1">
            <title>500 U CINRYZE (10-25 kg Body Weight)</title>
            <description>Single IV dose of 500 U CINRYZE</description>
          </group>
          <group group_id="O2">
            <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1000 U CINRYZE</description>
          </group>
          <group group_id="O3">
            <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1500 U CINRYZE</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Resolution of the Attack</title>
          <population>ITT-E population.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.58" lower_limit="11.48" upper_limit="37.35"/>
                    <measurement group_id="O2" value="10.00" lower_limit="1.57" upper_limit="22.33"/>
                    <measurement group_id="O3" value="29.07" lower_limit="1.58" upper_limit="102.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C1 Inhibitor (C1 INH) Antigen and Functional C1 INH Concentrations</title>
        <description>Data was not reported due to change in planned analysis.</description>
        <time_frame>Pre-dose, 2, 4, 8 hours post dose on Day 1; Day 2, 3, 5, 8</time_frame>
        <population>No participant agreed to obtain pharmacokinetic (PK) blood sampling for antigenic and functional C1 INH levels. Hence, it was planned not to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>500 U CINRYZE (10-25 kg Body Weight)</title>
            <description>Single IV dose of 500 U CINRYZE</description>
          </group>
          <group group_id="O2">
            <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1000 U CINRYZE</description>
          </group>
          <group group_id="O3">
            <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
            <description>Single IV dose of 1500 U CINRYZE</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C1 Inhibitor (C1 INH) Antigen and Functional C1 INH Concentrations</title>
          <description>Data was not reported due to change in planned analysis.</description>
          <population>No participant agreed to obtain pharmacokinetic (PK) blood sampling for antigenic and functional C1 INH levels. Hence, it was planned not to be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected through 1 week following the dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>500 U CINRYZE (10-25 kg Body Weight)</title>
          <description>Single IV dose of 500 U CINRYZE</description>
        </group>
        <group group_id="E2">
          <title>1000 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1000 U CINRYZE</description>
        </group>
        <group group_id="E3">
          <title>1500 U CINRYZE (&gt;25 kg Body Weight)</title>
          <description>Single IV dose of 1500 U CINRYZE</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Clinical Trial Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Change in C1 INH antigen and functional C1 INH concentrations endpoint was not analyzed as no participants agreed to additional and optional blood sampling. As a result, no PK parameters were calculated for this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Schranz, MD</name_or_title>
      <organization>Shire</organization>
      <phone>484-595-8940</phone>
      <email>jschranz@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

